Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences
• President & CEO, BIONAVIGEN, LLC, a biopharmaceutical virtual drug development company specializing in advising and consulting for all aspects of drug development, including discovery, preclinical development, CMC, translational sciences, clinical development and regulatory filing. • Selected by pharmaceutical peers as the 100 Most Inspiring People in Pharmaceutical Industry by PharmaVOICE in 2015 • Accomplished executive, inventor, and scientist with over 30 years of success with top biotechnology and pharmaceutical companies, including Merck, Johnson & Johnson, Medimmune, AstraZeneca.
Abstract: Nanomedicines are increasingly being used to diagnose, prevent, and treat human diseases. Nanotechnological advances are enabling targeted delivery of difficult to deliver innovative therapies, including gene editing and disease correcting gene delivery, highly lipophilic cytotoxic cancer drugs, mod RNA, etc. Although nanomedicines offer great opportunities for targeted delivery, they have increasingly faced safety, disposition, CMC and manufacturing challenges that have limited their utility. With special emphasis on safety and pharmacokinetics, the presentation will discuss the safety, pharmacokinetics, CMC, and other challenges in the development of nanomedicines with emphasis cancer therapeutic nanomedicines